On March 16, 2021, Solid Biosciences joined PPMD for a webinar to provide a safety and efficacy update on the ongoing IGNITE DMD phase I/II clinical study of SGT-001 microdystrophin gene therapy in patients with Duchenne muscular dystrophy. Research & Clinical Trial Webinars,Webinars 4 years ago You may also like 45:03 Webinar: Sarepta Therapeutics – Data update from MOMENTUM study, SRP-5051 12 months ago Research & Clinical Trial Webinars,Webinars sarepta 39:33 Webinar: NS Pharma – Overview of New Exon Skipping Trials: Brogidirsen and NS-050/NCNP-03 1 year ago Research & Clinical Trial Webinars,Webinars ns pharma 52:15 Overview of WVE-N531 and the FORWARD-53 Clinical Trial with Wave Life Sciences 1 year ago Research & Clinical Trial Webinars,Webinars wave life sciences,WVE-N531 29:09 PTC Therapeutics — EMFLAZA® Landscape in 2024 1 year ago Care Webinars,Webinars emflaza,ptc therapeutics 53:59 Dyne Therapeutics — Advancing DYNE-251, an Investigational Medicine for DMD 1 year ago Research & Clinical Trial Webinars,Webinars dyne therapeutics,DYNE-251 1:00:58 Navigating Steroid Choices: Understanding the Process, Pathways, and Policies 1 year ago Care Webinars,Webinars steroids 1:03:41 Community Update with Solid Biosciences on the New INSPIRE DUCHENNE Clinical Study of SGT-003 1 year ago Research & Clinical Trial Webinars,Webinars gene therapy,sgt-003,solid biosciences 59:54 Overview of Topline Results from Phase 3 EMBARK Study 1 year ago Research & Clinical Trial Webinars,Webinars sarepta «12345…25»Page 3 of 25